A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes

Inclusion Criteria

• •Signed and dated informed consent in accordance with GCP and local legislation
• •Adults (≥18 years) with the diagnosis of T2D
• •BMI of \<=45 kg/m2 at the time of presentation/screening
• •T2D mellitus inadequately controlled on therapy (HbA1c ≥7.0 and ≤10.0% \[53-86 mmol/mol\] at the time of initial presentation for screening and with the need for therapy escalation \[dose increase of existing therapy or additional prescription of insulin and/or OADs or change of therapy regimen\]) to achieve the therapeutic HbA1c target defined by the physician
• •Treatment with oral and/or injectable glucose lowering medications and/or long-acting insulin therapy